With well over 170 ETFs on the market covering diverse investment strategies, State Street offers a prime window into which funds — and market trends — are leading the pack in the near term.
Key Takeaways:
- Across State Street’s 170+ ETFs, the top five performers this past month are all tied to the healthcare industry.
- Specific areas of healthcare include: biotechnology, healthcare equipment, and insurance, among others
- The State Street SPDR S&P Pharmaceuticals ETF (XPH ) was the top performer with returns of 11.69% within the one-month period.
To see where the market momentum lies, we analyzed State Street’s top five performing ETFs over the one-month period spanning June 16 to July 16, 2026. Many would assume that any overarching theme attributed to these top five would likely be tech or AI. However, this was not the case — State Street’s top five ETFs were largely tied to the healthcare industry
State Street's Top 5: Healthcare's Summer Remedy
In fifth place, the State Street SPDR S&P Health Care Equipment ETF (XHE ) captured an 8.72% gain over the past month. The fund offers tactical exposure to companies engaged in healthcare supplies and equipment.
Next on the list is the State Street SPDR S&P Insurance ETF (KIE ) with a 9.12% gain over the period. KIE invests in a variety of insurance companies, such as insurance brokers, health insurance, property & casualty insurance, and others.
Sitting in third place is the State Street SPDR S&P Health Care Services ETF (XHS ), which saw a 10.78% return this month. The fund offers focused exposure to specified areas, including healthcare distributors, healthcare services, healthcare facilities, and managed healthcare.
See More: Q2 Earnings Preview: Tech & Energy Drive Growth Amid Healthcare Headwinds
The State Street SPDR S&P Biotech ETF (XBI ) was the second top performer, gaining 11.54% over the one-month period. True to its name, XBI offers investors targeted access to companies within the biotech industry.
Pharmaceuticals Top State Street's ETF Suite
Securing the top spot, the State Street SPDR S&P Pharmaceuticals ETF (XPH ) surged 11.69% from June 16 to July 16, 2026. The fund delivers targeted exposure to the pharmaceutical industry, drawing strong interest from the broader investment community. As of July 15, 2026, XPH has attracted over $160 million in net year-to-date inflows.
While State Street’s diverse ETF lineup accommodates all sectors and strategies, investors may want to consider these recent metrics. The healthcare industry is presenting clear opportunities right now and State Street is offering a variety of compelling ways to target them.
For more news, information, and analysis, visit the Equity ETF Content Hub.
